Linked Data API

Show Search Form

Search Results

436264
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-12-08
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, whether he plan to respond to the Accelerated Access Review: Interim Report, published in October 2015; and if he will make a statement. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 19241 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-12-15more like thismore than 2015-12-15
star this property answer text <br /><p>The Interim Report of Sir Hugh Taylor’s Accelerated Access Review (AAR) is a deliberately high level document that indicates direction of travel; as such, government will be responding to the AAR’s conclusions when its final recommendations are published early in the spring of 2016.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-12-15T16:30:10.483Zmore like thismore than 2015-12-15T16:30:10.483Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
105961
star this property registered interest false more like this
star this property date less than 2014-11-03more like thismore than 2014-11-03
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Bowel Cancer: Screening more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what assessment he has made of the results of pilots of flexible sigmoidoscopy screening for bowel cancer; and what plans he has for a nationwide rollout of such screening. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 212890 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-11-10more like thismore than 2014-11-10
star this property answer text <p>A randomised controlled trial funded by Cancer Research UK, the Medical Research Council and National Health Service Research and Development took place in 14 United Kingdom and six Italian centres, and evaluated screening for bowel cancer using a single Bowel Scope Screening (flexible sigmoidoscopy) between 55 and 64 years of age, removing small polyps by Bowel Scope Screening and providing full colonoscopy for &quot;high risk&quot; polyps. The study concluded that Bowel Scope Screening is a safe and practical test and, when offered only once between ages 55 and 64 years, confers a substantial and long lasting benefit. The UK National Screening Committee reviewed the evidence, and in April 2011 concluded that screening for bowel cancer using Bowel Scope Screening meets the United Kingdom National Screening Committee criteria for a screening test. In England its implementation will be managed by National Health Service Cancer Screening Programmes.</p><p> </p><p> </p><p> </p><p>As at 31 March 2014, 36.6% of Bowel Scope Screening centres in England were operational, exceeding the commitment of 30%<sup>1</sup>. As set out in the third annual report of <em>Improving Outcomes: A Strategy for Cancer</em> (December 2013), NHS England will work with Public Health England to help deliver the involvement of screening centres sufficient to meet the 60% commitment by March 2015 and to support preparatory steps in other screening centres to implement by the end of 2016.</p><p> </p><p> </p><p> </p><p>As at the end of October 2014, 20,603 examinations had taken place. 919 people had gone on to have a colonoscopy with 20 cancers being detected. A further 365 people have had an advanced adenoma found and removed.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p>[1] <a href="https://www.gov.uk/government/news/latest-bowel-cancer-screening-technique-reaps-benefits" target="_blank">https://www.gov.uk/government/news/latest-bowel-cancer-screening-technique-reaps-benefits</a></p><p> </p><p><strong> </strong></p><p> </p>
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property question first answered
less than 2014-11-10T17:54:15.273826Zmore like thismore than 2014-11-10T17:54:15.273826Z
star this property answering member
3918
star this property label Biography information for Jane Ellison more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
427717
star this property registered interest false more like this
star this property date less than 2015-11-10more like thismore than 2015-11-10
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Leukaemia: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what comparative assessment his Department has made of the (a) cost and (b) effectiveness of stem cell transplants and tyrosine kinase inhibitor therapies as treatments for chronic myeloid leukaemia. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 15807 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-11-19more like thismore than 2015-11-19
star this property answer text <p>As the treatments referred to are mutually exclusive, NHS England has no plans to carry out such an assessment. Patients will only be offered a transplant when they are unsuitable for tyrosine kinase inhibitor (TKI) treatment, or if this treatment has failed.</p><br /><p>Both imatinib (usually considered the first line option) and nilotinib are recommended by the National Institute for Health and Care Excellence as cost effective treatments for chronic myeloid leukaemia (CML). Dasatinib, bosutinib and ponatinib are only available for certain patients through the Cancer Drugs Fund.</p><p>In 2013, NHS England published a policy for the routine commissioning of allogeneic stem cell transplant for CML. This can be found at:</p><br /><p><a href="http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf" target="_blank">www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf</a></p><p>This policy allows for transplant in patients whose CML is refractory to TKI treatment, or where the patient is TKI intolerant. It takes into account expert advice from the British Society for Blood and Marrow Transplantation.</p><p>Based on the clinical pathway of care, no specific assessment of cost or effectiveness comparing blood and marrow transplantation with TKI has been undertaken.</p><br /><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p>
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property question first answered
less than 2015-11-19T17:31:59.333Zmore like thismore than 2015-11-19T17:31:59.333Z
star this property answering member
3918
star this property label Biography information for Jane Ellison more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
426559
star this property registered interest false more like this
star this property date less than 2015-11-05more like thismore than 2015-11-05
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Mental Health Services: Children and Young People more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what steps his Department is taking to improve children and young people's mental health services. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 15092 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-11-12more like thismore than 2015-11-12
star this property answer text <p>Children and young people’s mental health is a priority area for this Government. We are committed to delivering the vision set out in <em>Future in mind</em> through the launch of a major system-wide transformation programme working alongside our partners in Government and arm’s length bodies. This will improve access and make services more widely available across the country.</p><br /><p>To support this transformation, an additional£1.4 billion funding has been made available over the course of this Parliament for spending on children and young people’s mental health, of which we are spending £173 million this year, including £30 million on eating disorders. This will be used to improve community-based services so that young people are helped earlier and are less likely to need to go into hospital. It will also enable the expansion and extension of the Children and Young People’s Improving Access to Psychological Therapies programme so that a wider range of those who need it are able to access high quality and evidence-based interventions wherever they may live. All clinical commissioning groups have been asked to work with their partners to develop Local Transformation Plans to transform their local offer to improve children and young people’s mental health and wellbeing.</p><br /><p>A national programme of work will support local areas, including the extension and expansion of the use of evidence- based interventions, tackling stigma, improving data and information to inform greater transparency and accountability and developing a specialist and stronger workforce.</p>
star this property answering member constituency North East Bedfordshire more like this
star this property answering member printed Alistair Burt more like this
star this property question first answered
less than 2015-11-12T10:03:31.7Zmore like thismore than 2015-11-12T10:03:31.7Z
star this property answering member
1201
star this property label Biography information for Alistair Burt more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
92614
star this property registered interest false more like this
star this property date less than 2014-10-10more like thismore than 2014-10-10
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hives more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how many people in England have been diagnosed with chronic spontaneous urticaria in each year since 2010. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 209936 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-10-17more like thismore than 2014-10-17
star this property answer text <p>Information concerning the number of people with chronic spontaneous urticaria (also known as hives, welts or nettle rash) in England is not collected. However, the National Institute for Health and Care Excellence estimates that approximately 15% of people in the United Kingdom experience urticaria at some time in their lives and the lifetime prevalence of chronic urticaria is 0.5–1%.</p><p> </p> more like this
star this property answering member constituency North Norfolk more like this
star this property answering member printed Norman Lamb more like this
star this property grouped question UIN 209937 more like this
star this property question first answered
less than 2014-10-17T12:05:07.9317314Zmore like thismore than 2014-10-17T12:05:07.9317314Z
star this property answering member
1439
star this property label Biography information for Norman Lamb more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
92615
star this property registered interest false more like this
star this property date less than 2014-10-10more like thismore than 2014-10-10
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Hives more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how many people have chronic spontaneous urticaria in England. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 209937 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-10-17more like thismore than 2014-10-17
star this property answer text <p>Information concerning the number of people with chronic spontaneous urticaria (also known as hives, welts or nettle rash) in England is not collected. However, the National Institute for Health and Care Excellence estimates that approximately 15% of people in the United Kingdom experience urticaria at some time in their lives and the lifetime prevalence of chronic urticaria is 0.5–1%.</p><p> </p> more like this
star this property answering member constituency North Norfolk more like this
star this property answering member printed Norman Lamb more like this
star this property grouped question UIN 209936 more like this
star this property question first answered
less than 2014-10-17T12:05:07.6973534Zmore like thismore than 2014-10-17T12:05:07.6973534Z
star this property answering member
1439
star this property label Biography information for Norman Lamb more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
155948
star this property registered interest false more like this
star this property date less than 2014-11-17more like thismore than 2014-11-17
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Prescription Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what steps his Department is taking to encourage flexibility in the licensing process for potential new treatments for rare conditions. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 214491 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2014-11-24more like thismore than 2014-11-24
star this property answer text <p>Most new medicines for rare conditions are licensed by the European Commission.</p><p> </p><p>The European Union offers a range of incentives to encourage the development of these medicines in order to address unmet clinical need. These incentives include a period of 10 years market exclusivity, the provision of Protocol Assistance (scientific advice specifically tailored for orphan medicinal products) and fee reductions and waivers for regulatory procedures.</p><p> </p><p> </p><p> </p><p>Through the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom takes an active role in the decision making process at the European Medicines Agency’s Committee on Orphan Medicinal Products, ensuring applications for Orphan Drug designation of potential drug candidates for rare diseases are appropriately recognised, encouraging companies to develop their products further and recommending use of existing flexibilities such as conditional authorisation, authorisation under exceptional circumstances and accelerated assessment. The UK is actively involved in the European Medicines Agency’s adaptive licensing pilot that is exploring further use of these flexibilities. The MHRA has an Innovation Office that can offer advice and assistance to developers of drugs for rare diseases, including on the use of flexibilities.</p><p> </p><p><strong> </strong></p><p> </p><p>In addition, in the UK, the Early Access to Medicines Scheme aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.</p><p> </p><p> </p><p> </p><p>We are also commissioning an external review of the pathways for the development, assessment, and adoption of innovative medicines and medical technology. This review will consider how to speed up access for NHS patients to cost-effective new diagnostics, medicines and devices.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2014-11-24T17:23:13.99Zmore like thismore than 2014-11-24T17:23:13.99Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
419536
star this property registered interest false more like this
star this property date less than 2015-09-17more like thismore than 2015-09-17
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Incontinence more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what discussions he has had with NHS England regarding the (a) commissioning of continence services and (b) guidelines for continence services. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 10617 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-10-12more like thismore than 2015-10-12
star this property answer text <p>My Rt. hon. Friend the Secretary of State meets representatives from NHS England on a regular basis to discuss a wide range of issues, including the commissioning of local NHS services.</p> more like this
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property question first answered
less than 2015-10-12T11:01:41.933Zmore like thismore than 2015-10-12T11:01:41.933Z
star this property answering member
3918
star this property label Biography information for Jane Ellison more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
436265
star this property registered interest false more like this
star this property date remove maximum value filtermore like thismore than 2015-12-08
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Leukaemia: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, if he will ensure that the new Cancer Drugs Fund will increase patient access to medicines for acute myeloid leukaemia. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 19240 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-12-15more like thismore than 2015-12-15
star this property answer text <p>NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund.</p><br /><p>The consultation was published on 19 November 2015 and is open until 11 February 2016. It states that it is looking to put in place a solution that ensures patients have routine access to a greater range of cancer drugs, including earlier access to innovative drugs, while ensuring that cost-effectiveness is maintained. Further information is available at:</p><p>www.engage.england.nhs.uk/consultation/cdf-consultation</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-12-15T16:22:51.767Zmore like thismore than 2015-12-15T16:22:51.767Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this
434008
star this property registered interest false more like this
star this property date less than 2015-12-03more like thismore than 2015-12-03
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading NHS: Innovation more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what steps he is taking to ensure the outcome of the consultation on the future of the Cancer Drugs Fund is co-ordinated with and complements the recommendations of the Accelerated Access Review to ensure improved patient access to innovative treatments. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 18766 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-12-10more like thismore than 2015-12-10
star this property answer text <p>NHS England and the National Institute for Health and Care Excellence are currently consulting on draft proposals on the future direction of the Cancer Drugs Fund (CDF). The consultation is open until 11 February 2016 and further information is available at:</p><br /><p>www.engage.england.nhs.uk/consultation/cdf-consultation</p><br /><p>The Accelerated Access Review independently chaired by Sir Hugh Taylor, is working with key stakeholders on a range of options for accelerating patient access to innovative products, as set out in the interim report. This includes consideration of the impact of managed access schemes such as proposed in the CDF consultation.</p> more like this
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2015-12-10T14:04:50.203Zmore like thismore than 2015-12-10T14:04:50.203Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this